Arrhythmia Research Technology delays filing its Q2 earnings report

Arrhythmia Research Technology (HRT) says it didn't file its quarterly earnings report by the August 19 due date because of an ongoing review into the valuation of deferred tax assets.

On a preliminary basis, the company said it expects to report Q2 revenue rose 1.9% to $4.88M from a revised $4.79M a year ago.

It also sees its net loss for the three months ended in June narrowing to $328,022 from a $1.04M loss in the year-ago period.

The stock was halted earlier, but has since resumed trading.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs